Pharmacokinetic aspects of naloxone-precipitated morphine withdrawal in male and female prepubertal mice

17Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

It has been shown that the expression of the morphine (MOR) withdrawal syndrome precipitated by naloxone (NAL) is more intense in male mice than in females, but the reasons for this phenomenon remain uncertain. The purpose of the present study was to evaluate whether this sexual dimorphism might be due to differences in MOR and/or NAL plasma levels after a chronic treatment with MOR. Prepubertal Swiss male and female mice were rendered dependent by intraperitoneal (i.p.) injection of MOR (2 mg/kg), twice daily for 9 days. On day 10 dependent mice received NAL (6mg/kg, i.p.) 60 min after MOR injection. Blood samples were taken at different times in order to determine MOR and NAL plasma levels by gas chromatography-mass spectrometry (GC-MS) and high-performance liquid chromatography (HPLC), respectively. Pharmacokinetic analysis showed no differences between male and female mice either for MOR or for NAL. In conclusion, although males and females respond differentially to NAL-precipitated withdrawal, this dimorphic behavior would not be influenced by a pharmacokinetic factor. Copyright © 2007 John Wiley & Sons, Ltd.

Cite

CITATION STYLE

APA

Diaz, S. L., Hermida, M. P., Joannas, L. D., Olivera, M., Ridolfi, A., Villaamil, E. C., & Balerio, G. N. (2007). Pharmacokinetic aspects of naloxone-precipitated morphine withdrawal in male and female prepubertal mice. Biopharmaceutics and Drug Disposition, 28(6), 283–289. https://doi.org/10.1002/bdd.554

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free